Aroa Biosurgery logo

Aroa Biosurgery(ASX) ARX

Market CapA$174.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-61%
5 Year-56%
1 Year-28%
1 Month-8%
A$0.51
-2.89%
-0.02Today
Aroa Biosurgery last closing stock price
MetricPriceDate
Last closeAUD 0.512026-10-12
Aroa Biosurgery stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.02%AUD 0.502026-10-05
1 month-8.18%AUD 0.552026-09-11
3 month-15.13%AUD 0.602026-07-14
Year to date-31.76%AUD 0.742025-12-31
1 year-28.37%AUD 0.712025-10-10
3 year-29.86%AUD 0.722023-10-13
5 year-56.09%AUD 1.152021-10-13
Since inception-61.48%AUD 1.352020-07-24

Aroa Biosurgery Financials at a Glance

Market Cap

A$174.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$138.11M

Net Income (TTM)

A$4.16M

EPS (TTM)

A$0.01

P/E Ratio

43.91

Dividend

A$0.00

Beta (Volatility)

-0.02 (Low)

Price

A$0.51

Volume

122,781

Open

A$0.53

Previous Close

A$0.51

Daily Range

A$0.50 - A$0.53

52-Week Range

A$0.48 - A$0.80

Estimated Earnings Date

Nov 24, 2026

ARX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aroa Biosurgery

Aroa Biosurgery Limited is a regenerative medicine company focused on developing, producing, and distributing medical solutions for wound and tissue repair. Utilizing innovative extracellular matrix (ECM) technology, the company operates in the United States and internationally, offering a range of products designed for both acute and chronic wound management.

Products and Services
  • Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for wound management
  • Myriad Matrix, an engineered ECM device for soft tissue repair
  • Reinforced Bioscaffolds for surgical applications like hernia repair
Growth Outlook
  • Revenue increased to AUD 50.82 million in the latest quarter
  • Gross profit margin remains strong at 86.4% for Q4 2026
  • Significant cash reserves of AUD 17.54 million support future growth initiatives
Financial Highlights
  • Net income of AUD 5.15 million reported for Q4 2026
  • Operating income margin improved to 11.4% in the latest quarter
  • Current ratio of 4.77 indicates strong liquidity position
Aroa Biosurgery Limited is well-positioned in the healthcare sector, particularly in the medical devices industry. The company's innovative product offerings, combined with a robust financial performance, highlight its potential for growth. The recent quarterly results demonstrate a significant increase in revenue and net income, reflecting effective management and operational efficiency. With a strong cash position, Aroa is poised to capitalize on future opportunities in the regenerative medicine market.
AI Generated • Sep 21, 2026

Industry

Biotechnology

CEO

Brian Roderick Ward, PhD, MBA

Headquarters

Auckland, AU 2022, NZ

ARX Financials

Key Financial Metrics (TTM)

Gross Margin

57.65%

Operating Margin

4.73%

Net Income Margin

3.01%

Return on Equity

4.97%

Return on Capital

4.95%

Return on Assets

4.14%

Earnings Yield

2.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$174.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

345.47M

Volume

122.78K

Avg. Volume

240.94K

Financials (TTM)

Gross Profit

A$79.63M

Operating Income

A$6.53M

EBITDA

A$14.48M

Operating Cash Flow

A$13.76M

Capital Expenditure

-A$1.45M

Free Cash Flow

A$12.31M

Cash & ST Invst.

A$22.60M

Total Debt

A$5.31M

Aroa Biosurgery Performance Analysis

Aroa Biosurgery annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31AUD 57,733,30354.4%
20242024-03-31AUD 64,027,38210.9%
20252025-03-31AUD 77,099,03820.4%
20262026-03-31AUD 92,284,28219.7%
Aroa Biosurgery sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-300.4%
Q22025-09-3097.7%
Q32025-12-31-38.1%
Q42026-03-3199.8%
Aroa Biosurgery annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31AUD -0.00-95.7%
20242024-03-31AUD -0.032770.0%
20252025-03-31AUD -0.01-64.8%
20262026-03-31AUD 0.01N/A
Aroa Biosurgery sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-157.1%
Q22025-09-30-94.4%
Q32025-12-31294.3%
Q42026-03-31110.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$50.82M

+145.6%

Gross Profit

A$43.92M

+150.2%

Gross Margin

86.42%

N/A

Market Cap

A$174.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$639.06K

N/A

Employees

273

N/A

Net Income

A$5.15M

+2284.1%

EBITDA

A$8.12M

+155.4%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$22.60M

+12.3%

Total Debt

A$5.31M

-8.9%

Accounts Receivable

A$33.84M

+128.0%

Inventory

A$5.01M

-33.3%

Long Term Debt

A$4.08M

-15.3%

Short Term Debt

A$1.23M

+21.3%

Return on Assets

4.14%

N/A

Return on Invested Capital

7.51%

N/A

Free Cash Flow

A$4.94M

+597.6%

Operating Cash Flow

A$5.44M

+420.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCC.AXOrthocell Limited
A$0.67-2.90%
TTX.AXTetratherix Ltd.
A$6.41+1.10%
TRP.AXTissue Repair Ltd
A$0.09+0.00%
OSX.AXOsteopore Limited
A$0.00-14.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$34.39+1.78%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$139.76-1.94%
WFFWf
$12.29+499.51%
IRENIren
$35.19-1.46%

Questions About ARX

What is the current price of Aroa Biosurgery?

Aroa Biosurgery is trading at A$0.51 per share.

What is the 52-week range for Aroa Biosurgery?

Over the past 52 weeks, Aroa Biosurgery has traded between A$0.48 and A$0.80.

How much debt does Aroa Biosurgery have?

As of the most recent reporting period, Aroa Biosurgery reported total debt of A$5.31M.

How much cash does Aroa Biosurgery have on hand?

Aroa Biosurgery reported A$17.54M in cash and cash equivalents in its most recent financial results.

What is Aroa Biosurgery’s dividend yield?

Aroa Biosurgery does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.